

# **Prevention of Migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device (PREMICE): a multi-centre, randomised, sham-controlled trial**

Jean Schoenen<sup>1</sup>, Bart Vandersmissen<sup>2</sup>, Sandrine Jeanette<sup>3</sup>, Luc Herroelen<sup>4</sup>, Michel Vandenheede<sup>5</sup>

<sup>1</sup> Headache Research Unit. Department of Neurology & GIGA – Neurosciences.

Liège University, CHU-Sart Tilman. T4 (+1). B36., B-4000 LIEGE. Belgium.

<sup>2</sup> CHU Erasme (ULB)-clinique de l'Europe à Bruxelles, B-1040 BRUSSELS

<sup>3</sup> Neurology CHU Charleroi, B-6000 CHARLEROI, Belgium

<sup>4</sup> AZ Gasthuisberg (KUL), B-3000 LEUVEN, Belgium

<sup>5</sup> CHC Espérance Liège, B-4420 MONTEGNEE, Belgium

Email addresses:

JS: [jschoenen@ulg.ac.be](mailto:jschoenen@ulg.ac.be)

BV: [bartvdsm@hotmail.com](mailto:bartvdsm@hotmail.com)

SJ: [sandrine.jeanette@chu-charleroi.be](mailto:sandrine.jeanette@chu-charleroi.be)

LH: [luc.herroelen@skynet.be](mailto:luc.herroelen@skynet.be)

MV: [michel.vandenheede@chc.be](mailto:michel.vandenheede@chc.be)



LIEGE, Belgium, November 8, 2011 /PRNewswire/ --

**PREMICE clinical trial proves Cefaly® medical device efficacy in migraine prevention and points out that Cefaly® has the best safety-efficacy ratio compared to other treatments.**

On Monday 7th of November a press conference took place in Liege Science Park. Professor Jean Schoenen, principal investigator, neurologist and professor at Liege University (Belgium) presented the results of PREMICE (Prevention Migraine Cefaly) a multicenter randomized double-blind placebo controlled clinical trial for migraine prevention with the Cefaly® neurostimulator.

The clinical trial was conducted in 5 Belgian university hospitals on 67 patients. The results prove the efficacy of the Cefaly® compared to placebo for migraine prevention. At 3 months of treatment the 50% responder rate was significantly greater in the Cefaly® group (38,1%) than in the placebo group (12,1%). Seventy percents of patients declared they were satisfied or very satisfied with the Cefaly® treatment. The drug consumption reduction is very impressive in the Cefaly® group (-37%) compared to the placebo group (+0.5%). Cefaly® responder group drug consumption reduction was -75%!

Without noticeable side effects or contraindications, Cefaly® is very safe. Cefaly® has a similar efficacy than preventative drugs, but without side effects. Consequently, Cefaly® has the best safety-efficacy ratio of all migraine treatments.

Prof. Schoenen: "This clinical trial has been implemented according to the highest quality standard and it proves that Cefaly® is efficient for migraine prophylaxis. Efficacy is similar with the most efficient preventative drugs but with the great advantage of having no side effects."

Cefaly® is an innovative medical device protected by a series of patents. This is the first cranial external neurostimulation device on the market. Cefaly® neurostimulation is applied to the upper branch of the trigeminal nerve. A self-adhesive electrode is applied on the forehead and the device is placed on this

electrode in the position of a pair of glasses. Very accurate pulses are transmitted through the electrode to the nerve endings of the trigeminal nerve.

STX-Med Company is a startup based in Liege (Belgium), which launched the Cefaly® technology project in 2005. The company STX-Med is ISO Medical. Cefaly® device has the medical CE-marked. It is available on the European market for 295 € and in Canada as well.

<http://www.cefaly.com/>